SCHEMBL673678

SCHEMBL673678

O=C(NO)c1ccc(NC(=O)c2ccccc2)cc1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 4/20 0.89
HDAC6 Q9UBN7 4/20 0.89
HDAC2 Q92769 3/20 0.89
NPC1 O15118 4/20 0.75
RAB9A P51151 4/20 0.75
MEN1 O00255 3/20 0.75
KMT2A Q03164 3/20 0.75
KDM4E B2RXH2 2/20 0.75
POLB P06746 2/20 0.75
HDAC1 Q13547 2/20 0.73
PTPN1 P18031 3/20 0.72
HDAC3 O15379 2/20 0.72
CA12 O43570 1/20 0.72
CA1 P00915 1/20 0.72
IDO1 P14902 1/20 0.72
ALOX15 P16050 1/20 0.72
CA9 Q16790 1/20 0.72
HDAC7 Q8WUI4 1/20 0.72
HSD17B10 Q99714 1/20 0.72
NCOR2 Q9Y618 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14643098 0.94 HDAC8 (1.00) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL14715824 0.92 NPC1 (0.88) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL18103163 0.92 NPC1 (0.88) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL675993 0.91 HDAC8 (0.79) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL26953087 0.90 PTPN1 (0.88) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL126415 0.89 PTPN1 (0.87) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL3033694 0.89 HDAC2 (0.89) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL15482224 0.88 HDAC6 (0.75) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL14715847 0.87 PTPN1 (0.84) HDAC8HDAC6HDAC2NPC1RAB9A
SCHEMBL5344166 0.86 NPC1 (1.00) HDAC8HDAC6HDAC2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115090-B2 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2015-08-25 US claimed
EP-1660437-B1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2008-10-15 EP claimed
US-7282522-B2 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2007-10-16 US claimed
US-20070225373-A1 Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-09-27 US claimed
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2006-11-09 US claimed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP claimed
EP-1696898-A2 ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2006-09-06 EP claimed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP claimed
WO-2005055928-A2 ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2005-06-23 WO claimed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO claimed
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
EP-1696898-B1 ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS UNIV OHIO STATE RES FOUND (US) 2015-11-18 EP disclosed
US-9115090-B2 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2015-08-25 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP disclosed
EP-1696898-A2 ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2006-09-06 EP disclosed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP disclosed
WO-2005055928-A2 ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2005-06-23 WO disclosed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC8 4/4885HDAC6 10/4885HDAC2 3/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC8 4/4885HDAC6 10/4885HDAC2 3/4885
US-20070225373-A1 Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase HDAC1, BAZ2B, HDAC11 HDAC8 14/4885HDAC6 13/4885HDAC2 5/4885
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof HDAC7, SIRT7, HCAR1 HDAC8 72/4885HDAC6 201/4885HDAC2 211/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC8 4/4885HDAC6 10/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.